Bone marrow suppression is the primary cause of death in individuals inadvertently exposed to high doses of radiation. While a radioprotectants exist that will decrease toxicity when given before exposure to radiation, there are currently no effective therapies to mitigate bone marrow toxicity of radiation when given after radiation exposure, the firm points out.

G-Zero is actively progressing small molecule radiomitigants to provide protection of bone marrow and other organs including the kidney and lung from radiation exposure. These molecules transiently arrest the cell cycle of hematopoeitic progenitor and stem cells in the bone marrow. This transient arrest, termed pharmacological quiescence, or Pharmacoquiescence™ (PQ™), exploits that fact that when cells are arrested in Go/G1 of the cell cycle, cells are more resistant to DNA-damaging insults.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.